DAX22.139 -1,1%ESt505.215 -1,7%Top 10 Crypto11,43 -5,5%Dow42.225 +0,6%Nas17.601 +0,9%Bitcoin75.966 +0,4%Euro1,1016 +1,7%Öl72,69 -0,9%Gold3.128 -0,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Tesla A1CX3T Rheinmetall 703000 NVIDIA 918422 RENK RENK73 Amazon 906866 Mercedes-Benz Group (ex Daimler) 710000 Volkswagen (VW) vz. 766403 thyssenkrupp 750000 Lufthansa 823212 Bayer BAY001 Novo Nordisk A3EU6F HENSOLDT HAG000 Siemens Energy ENER6Y Commerzbank CBK100 Deutsche Telekom 555750
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Trump verkündet riesiges Zollpaket: DAX tiefrot -- Teils kräftige Verluste in Asien - Nikkei bricht ein -- Gold mit Rekord -- Bankaktien, Immoaktien, Sportartikelhersteller, Autoaktien im Fokus
Top News
Siemens-Aktie deutlich schwächer: Übernahme von Dotmatics Siemens-Aktie deutlich schwächer: Übernahme von Dotmatics
BYD-Aktie & Co. nach Zoll-Hammer schwach, Xiaomi gegen den Trend stark: Tesla-Rivalen mit starkem Absatzwachstum BYD-Aktie & Co. nach Zoll-Hammer schwach, Xiaomi gegen den Trend stark: Tesla-Rivalen mit starkem Absatzwachstum
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Vanda Pharmaceuticals Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
3,98 EUR -0,12 EUR -2,93 %
FSE
4,60 USD +0,10 USD +2,22 %
nachbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.239,29 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA0JJT3

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS9216591084

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolVNDA

Vanda Pharmaceuticals Aktien News

DatumMeistgelesen
BenzingaForecasting The Future: 5 Analyst Projections For Vanda Pharmaceuticals
PR NewswireVanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia
PR NewswireVanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"
Wer­bungVanda Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
ZacksVanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates
PR NewswireVanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
PR NewswireVanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
PR NewswireVanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
PR NewswireVanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis
BenzingaFDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate
PR NewswireVanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review
ZacksIs it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?
PR NewswireVanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera
PR NewswireVanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences
PR NewswireVanda Pharmaceuticals Reports Third Quarter 2024 Financial Results
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
BenzingaOver 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst
PR NewswireVanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
PR NewswireVanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
MotleyFoolWhy Vanda Pharmaceuticals Stock Sank by Nearly 6% Today
PR NewswireFDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis
PR NewswireVanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference
PR NewswireVanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference
PR NewswireVanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference
PR NewswireVanda Pharmaceuticals Reports Second Quarter 2024 Financial Results
PR NewswireVanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024
BenzingaWhat's Going On With Vanda Pharmaceuticals Shares Today?
BenzingaVanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
PR NewswireVanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders
PR NewswireVanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak
BenzingaVanda Pharmaceuticals Receives Another Takeover Proposal, Considers $466M Deal
PR NewswireVanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.
PR NewswireVanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference
PR NewswireVanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®
PR NewswireVanda Pharmaceuticals Announces Presentations at SLEEP 2024
PR NewswireVanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its Shareholders
PR NewswireVanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness
PR NewswireVanda Pharmaceuticals Reports First Quarter 2024 Financial Results
Wer­bung

Vanda Pharmaceuticals News

Vanda Pharmaceuticals News: auf dieser Seite finden Sie alle Vanda Pharmaceuticals News und Nachrichten zur Vanda Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Vanda Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Vanda Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.